This is both a watershed moment for our community and a sobering one.

Rasonque (daraxonrasib) is the first medicine to broadly target RAS, the protein mutated in most pancreatic cancers, and in a Phase 3 trial it doubled median survival compared with chemotherapy (13.2 months vs 6.7 months). For the first time, we have a targeted therapy that attacks the main driver of this disease.

At the same time, the current list price, more than $475,000 (USD) a year makes this one of the most expensive cancer treatments in history. A drug that changes survival for some but not for most changes the narrative, not the outcome.

As a patient advocacy organization, our stance is clear: We welcome this progress. After decades of chemotherapy as the backbone of care, a RAS-targeted pill is proof that pancreatic cancer is treatable. As a founding member of the World Pancreatic Cancer Coalition we will work with our global partners to ensure equitable access to current and future breakthroughs.

And most importantly, we will keep pushing for what this drug alone cannot deliver: earlier detection. Even a transformative therapy helps too few if most patients are diagnosed after the disease has spread.

Six extra months can mean a graduation, a wedding, a new grandchild, or time for meaningful end‑of‑life conversations. And that matters. But we cannot stop here. Our goal remains six-plus years, not six months and that will require earlier diagnosis, faster pathways through the health system, and investment that matches the urgency of this disease.

Momentum is building. This is just the beginning.

‍

Read the news release:

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

Image retrieved from Revolution Medicines.